There Is One Heart Food Most People Have Never Heard Of
You can eat the salmon. Add the omega-3s. Load up on the leafy greens. But there is one food behind some of the most striking cardiovascular research of the last decade, and almost nobody has it on their plate. Below is my breakdown of what it is, what the studies found, and why the amount matters more than anything else.
Most of the heart-healthy foods you already know support the body by feeding it something. Fiber binds cholesterol. Omega-3s calm inflammation. Potassium helps the vessels relax. They are all worth eating. But there is one traditional food that does something different, and it is the one I get the most questions about.
It is called natto. A fermented soybean dish eaten in Japan for centuries. It is an acquired taste, and most people outside Japan never touch it. But inside it is an enzyme called nattokinase, and that enzyme is what researchers have spent the last two decades studying.
The regions of Japan that eat the most natto tend to show some of the lowest rates of cardiovascular trouble in the world. That observation is what sent scientists looking. What they found is worth walking through carefully.
What the Research Actually Measured
The Takayama study followed roughly 29,000 adults in central Japan for sixteen years. The residents who ate the most natto died of cardiovascular disease about 25% less often than those who ate the least. Unfermented soy showed no such association. The fermentation, and the enzyme it produces, appeared to be doing the work.
In 2017, Ren and colleagues documented a 36.6% reduction in carotid artery plaque over twenty-six weeks of nattokinase supplementation.
Then came Chen 2022, published in Frontiers in Cardiovascular Medicine. The largest nattokinase study to date. 1,062 adults. Twelve months. It is important to be precise here. This was a retrospective observational study, not a randomized controlled trial. But the size and the length of it make it hard to ignore.
The group taking roughly 10,800 FU per day saw carotid plaque area come down substantially on ultrasound, from 24.9 mm² to 15.94 mm². Carotid wall thickness dropped. Blood pressure improved. Triglycerides came down 15%. LDL cholesterol fell 18%. HDL, the protective kind, rose 15%.
The group taking roughly 3,600 FU per day saw none of those changes. Same enzyme. Same study. The dose was the difference.
Why That One Marker Carries So Much Weight
Arterial plaque builds quietly, for years, without symptoms. It climbs with age. Around 9% of Americans in their late fifties live with heart disease, and by the seventies that figure more than doubles. The buildup does not announce itself. By the time it does, the vessel is already narrowed.
That is why what the studies measured matters. Many heart supplements move a single number on a lab sheet. What stood out in this research was that when plaque came down, the other markers tended to move alongside it.
It Works on Something Most Heart Routines Leave Untouched
Most of my patients are already doing something for their heart. A cholesterol pill. A blood pressure pill. Aspirin. Diet changes. Walking. These are good steps. Each one targets one piece of the picture.
None of them work on fibrin.
Fibrin is the tough protein involved in how blood flows and how existing buildup holds together. Aspirin helps stop new clots from forming. It does not act on what is already there. A cholesterol pill lowers cholesterol production. It does not address the structural buildup that has been layering on for decades.
Nattokinase is one of the few natural compounds studied for how it supports the body’s own ability to break fibrin down. It fills a gap the other steps were not designed to fill. That is why I stopped thinking of it as a competitor to what my patients already do, and started thinking of it as the piece most of them were missing.
Why the Form Matters as Much as the Dose
You do not have to eat natto to get nattokinase. The enzyme can be taken on its own, which is good news for anyone who has smelled the real thing. But here is the catch. Nattokinase is a protein, and stomach acid breaks proteins down. A standard capsule dissolves in the stomach within minutes, and much of the enzyme can be destroyed before it ever reaches the small intestine where absorption happens.
Enteric coating is a pH-sensitive barrier that stays intact in stomach acid and dissolves only further down, in the intestine. The enzyme arrives where it needs to be. Many nattokinase products skip it. If the label does not say enteric-coated, it is worth asking why.
The Formula I Could Not Find on a Shelf
For years, I wrote down an ingredient list and told patients to assemble it themselves. The enzyme at the right dose, the co-factors, the right form. Most never did. Nobody wants to take a handful of softgels from a row of different bottles every morning.
The product I now point patients toward is called Hale Heart.
10,800 FU of nattokinase per serving, enteric-coated. That is the same dose associated with the changes in the Chen 2022 research, not the lower amount that showed nothing. Most of what sits on a pharmacy shelf comes in around 2,000 FU. Hale Heart is built on the dose the research actually used.
Paired with CoQ10 for heart muscle energy. Vitamin K2 for healthy arteries. Turmeric and bromelain for a healthy inflammatory response. Olive leaf for vascular support.
Every ingredient on the label with its exact dose. Third-party tested. No proprietary blends. Enteric-coated softgels designed to carry the enzyme past stomach acid intact.
What Patients Are Telling Me
- Chen H, et al. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, 9, 964977. (Retrospective observational.)
- Ren NN, et al. (2017). A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi, 97(26), 2038-2042.
- Nagata C, et al. (2017). Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: The Takayama study. American Journal of Clinical Nutrition, 105(2), 426-431.
- Sumi H, et al. (1990). Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of Nattokinase. Acta Haematologica, 84(3), 139-143.
